Nabumetone
Nabumetone is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Nabumetone; Generic name: NABUMETONE; Drug class: Nonsteroidal Anti-inflammatory Drug [EPC].
| Brand name | Nabumetone |
|---|---|
| Generic name | NABUMETONE |
| Drug class | Nonsteroidal Anti-inflammatory Drug [EPC] |
| Manufacturer | Asclemed USA, Inc. |
| Used for | INDICATIONS AND USAGE Carefully consider the potential benefits and risks of nabumetone tablets, USP and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets, USP are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. |
| Dosage | DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of nabumetone tablets and other treatment options before deciding to use nabumetone tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). After observing the response to initial therapy with nabumetone tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. Osteoarthritis and Rheumatoid Arthritis: The recomm |
| Warnings | WARNINGS CARDIOVASCULAR EFFECTS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAI |
| Active ingredient(s) | NABUMETONE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04a71deb-2c9d-436c-a574-e5991b6a5248 |